

Psychological State in Primary Idiopathic Galactorrhea

Dalia Megido, MD, Yair Yodfat, MD, Hannah Kedar, MA
Jerusalem, Israel

Primary idiopathic galactorrhea is defined as galactorrhea in the presence of normal menses, normal prolactin and thyroid hormone levels, a negative drug history, and a normal skull and sella roentgenogram. Primary idiopathic galactorrhea is a rather common condition among galactorrheic women, accounting for 30 to 40 percent of the diagnoses,¹ or even more.² No cause has been demonstrated for primary idiopathic galactorrhea, and some investigators have suggested that the condition "may be of no clinical significance."³ Some authors have suggested that stress may be involved as a possible etiologic factor of "galactorrhea-amenorrhea syndrome."⁴

In the present study the psychological state of five patients who suffered from primary idiopathic galactorrhea were evaluated using the Minnesota Multiphasic Personality Inventory (MMPI)-168 questionnaire.⁵

METHODS

The study was carried out in a rural primary care practice in Israel with a total population of 4,200. The entire population is insured by the Labor Sick Fund (Kupat Holim) and benefits from health services offered by this fund.

All new diagnoses are coded in computer files. Six women were found to complain of galactorrhea during the two-year period of 1983 to 1984. The galactorrhea was bilateral in all cases and appeared only when pressing the breast. The duration of the symptom ranged from a few months to two years. One patient moved from the area, while the rest were tested to rule out organic endocrinological or drug causes. Examination included prolactin and thyroid hormone levels and skull x-ray examination. The thyroid stimulating hormone (TSH) levels

of all patients were not tested. One patient had normal TSH levels (2.7 mIU/mL) (patient 3), and one patient had normal results on a thyroid scan using the isotope iodine 131 (patient 5). The other three showed normal free triiodothyronine (T₃), free thyroxine (T₄), and free thyroxine index (FTI) levels at the time of the complaint and at the two year follow-up. The MMPI-168 questionnaire was completed, and a personality profile was defined for each woman.⁶

RESULTS

The age, history, and clinical and laboratory characteristics are presented in Table 1. All five patients had regular menses, and in none was the galactorrhea associated with recent pregnancy. The hormonal profiles and skull x-ray examinations were normal in all the women. The final diagnosis of all these patients was therefore primary idiopathic galactorrhea.

The continuous follow-up of the patients of up to two years did not reveal any development of additional symptoms or signs that could change the diagnosis of primary idiopathic galactorrhea.

The T scores of the MMPI-168 scales are presented in Table 2. Normal scores range between 45 and 59. The moderate elevation range is between 60 and 69, while any score above 70 indicates a pathological value.

Pathological mean T scores were found in the scales indicating depression, hysteria, paranoia, and schizophrenia. The mean high score for the schizophrenia scale was due to two markedly high scores found in patients 1 and 5. The high scores indicate acute, severe situational stress rather than a schizophrenic trend.⁷ The other pathological scales indicate that the patients suffered from "markedly depressed mood either about life or about themselves."⁷ The patients were, in general, "naive, lacking in insight into their own behavior and that of others, and they denied any psychological problems." "Under stress-specific physical complaints," it appears that these

Submitted, revised, March 26, 1987.

From the Department of Family Medicine, Hadassah Medical School, The Hebrew University, and Kupat Holim, Jerusalem, Israel. Requests for reprints should be addressed to Dr. Dalia Megido, Department of Family Medicine, Hadassah Medical School, The Hebrew University, POB 1172, Jerusalem, Israel.

TABLE 1. CLINICAL AND LABORATORY CHARACTERISTICS OF PATIENTS WITH GALACTORRHEA

Case No.	Age (years)	Marital Status	Number of Previous Pregnancies	Menses	Physical Examination	Prolactin (ng/mL)	T ₄ mIU/mL	Skull and Sella X-ray Examination
1	24	Married	3	Regular	Normal	3.5	8.9	Normal
2	33	Married	4	Regular	Normal	13.9	5.0	Normal
3	26	Married	1	Regular	Normal	5.5	7.6	Normal
4	31	Married	2	Regular	Normal	20.5	6.5	Normal
5	34	Single	1	Regular	Normal	14.1	7.0	Normal

TABLE 2. T SCORES OF THE MMPI-168 (pathological values > 70)

Patient No.	Validity Scales			Clinical Scales									
	L	K	F	1 Hypochondria	2 Depression	3 Hysteria	4 Psychotic Deviation	5 Male/Female	6 Paranoia	7 Psychasthenia	8 Schizophrenia	9 Mania	10 Introversion
1	53	86	38	78	75	87	83	63	82	69	101	65	45
2	50	64	53	44	73	63	55	39	67	36	63	33	58
3	63	55	53	52	75	80	48	55	73	41	52	48	70
4	63	50	74	35	67	77	41	45	62	25	37	43	53
5	53	100	38	62	73	64	67	78	105	61	107	48	70
Mean	56.4	71	51.2	54.2	<u>72.6</u>	<u>74.2</u>	58.8	56	<u>77.8</u>	46.4	<u>72</u>	47.4	59

patients are likely to be "suspicious, hostile and overly sensitive."⁷

DISCUSSION

The estimated annual incidence of galactorrhea in the study population was 0.07 percent. Nyirjesy² found a rate of 0.6 percent in a gynecological department. Friedman and Goldfiel,³ however, reported that the prevalence of galactorrhea among women with a history of pregnancy was 25 percent. His study was conducted in a family planning clinic. The difference in incidence may be due to the different patient population.

The reported rates of primary idiopathic galactorrhea among all galactorrheic women varied between 30 and 40 percent.¹⁻³ These rates were calculated in hospitals or specialized clinics, however, where the selection of patients differs from that of a primary care clinic. The evidence that all five of the patients studied had primary idiopathic galactorrhea may indicate that the proportion of incidence is higher when the entire population is screened.

A rather unique psychological profile was found of the women studied: all patients had at least one pathological scale on the MMPI-168 scores. Patient 5 had four and patient 1 had six pathological scales. Both evidenced severe situational stress. Tyson et al⁴ had suggested that psychological disturbances may be related to the galactorrhea-amenorrhea syndrome. Zacur et al⁸ found that two out of three women with galactorrhea-amenorrhea syndrome had distorted psychometric tests, mainly excessive depression, and Nicolls et al⁹ have demonstrated that rats began to lactate when exposed to nonspecific stress.

Naguib et al¹⁰ found that 8 out of 12 women with symptoms of idiopathic galactorrhea had hypothyroidism, and the other four had markedly elevated levels of adrenalin (suggesting stress). All complained of physical fatigue and were found to suffer from depression and obsessions. Psychological tests did not discriminate between the hypothyroid and idiopathic patients, and these test results may be related to hypothyroidism rather than galactorrhea.

Although stress can cause a loss of hypothalamic control

continued on page 638

Halcion®
Tablets (triazolam) 

INDICATIONS AND USAGE: HALCION Tablets are indicated in the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.

It is recommended that HALCION not be prescribed in quantities exceeding a one-month supply.

CONTRAINDICATIONS: Patients with known hypersensitivity to this drug or other benzodiazepines.

HALCION is contraindicated in pregnant women due to potential fetal damage. Patients likely to become pregnant while receiving HALCION should be warned of the potential risk to the fetus.

WARNINGS: Overdosage may occur at four times the maximum recommended therapeutic dose. Patients should be cautioned not to exceed prescribed dosage.

Because of its depressant CNS effects, patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness and also about the simultaneous ingestion of alcohol and other CNS depressant drugs.

Anterograde amnesia and paradoxical reactions have been reported with HALCION and some other benzodiazepines.

PRECAUTIONS: *General:* In elderly and/or debilitated patients, treatment should be initiated at 0.125 mg to decrease the possibility of development of oversedation, dizziness, or impaired coordination. Caution should be exercised in patients with signs or symptoms of depression which could be intensified by hypnotic drugs. Suicidal tendencies and intentional overdosage is more common in these patients. The usual precautions should be observed in patients with impaired renal or hepatic function and chronic pulmonary insufficiency. *Information for Patients:* Alert patients about: (a) consumption of alcohol and drugs, (b) possible fetal abnormalities, (c) operating machinery or driving, (d) not increasing prescribed dosage, (e) possible worsening of sleep after discontinuing HALCION. *Laboratory Tests:* Not ordinarily required in otherwise healthy patients. *Drug Interactions:* Additive CNS depressant effects with other psychotropics, anticonvulsants, antihistaminics, ethanol, and other CNS depressants. Pharmacokinetic interactions of benzodiazepines with other drugs have been reported, e.g., coadministration with either cimetidine or erythromycin reduced clearance, prolonged elimination half-life, and approximately doubled plasma levels of triazolam, hence increased clinical observation and consideration of dosage reduction may be appropriate. *Carcinogenesis, Mutagenesis, Impairment of Fertility:* No evidence of carcinogenic potential was observed in mice during a 24-month study with HALCION in doses up to 4000 times the human dose. *Pregnancy:* Benzodiazepines may cause fetal damage if administered during pregnancy. The child born of a mother who is on benzodiazepines may be at some risk for withdrawal symptoms and neonatal flaccidity during the postnatal period. *Nursing Mothers:* Administration to nursing mothers is not recommended. *Pediatric Use:* Safety and efficacy in children below the age of 18 have not been established.

ADVERSE REACTIONS: During placebo-controlled clinical studies in which 1003 patients received HALCION Tablets, the most troublesome side effects were extensions of the pharmacologic activity of HALCION, e.g. drowsiness, dizziness, or lightheadedness.

	HALCION	Placebo
Number of Patients	1003	997
% of Patients Reporting:		
Central Nervous System		
Drowsiness	14.0	6.4
Headache	9.7	8.4
Dizziness	7.8	3.1
Nervousness	5.2	4.5
Lightheadedness	4.9	0.9
Coordination Disorder/Ataxia	4.6	0.8
Gastrointestinal		
Nausea/Vomiting	4.6	3.7

In addition, the following adverse events have been reported less frequently (i.e., 0.9-0.5%): euphoria, tachycardia, tiredness, confusional states/memory impairment, cramps/pain, depression, visual disturbances.

Rare (i.e., less than 0.5%) adverse reactions included constipation, taste alterations, diarrhea, dry mouth, dermatitis/allergy, dreaming/nightmares, insomnia, paresthesia, tinnitus, dyesthesia, weakness, congestion, death from hepatic failure in a patient also receiving diuretic drugs.

The following adverse events have been reported in association with the use of benzodiazepines: dystonia, irritability, anorexia, fatigue, sedation, slurred speech, jaundice, pruritus, dysarthria, changes in libido, menstrual irregularities, incontinence and urinary retention.

As with all benzodiazepines, paradoxical reactions such as stimulation, agitation, increased muscle spasticity, sleep disturbances, hallucinations and other adverse behavioral effects may occur rarely and in a random fashion. Should these occur, use of the drug should be discontinued.

No laboratory changes were considered to be of physiological significance.

When treatment is protracted, periodic blood counts, urinalysis and blood chemistry analyses are advisable.

Minor changes in EEG patterns, usually low-voltage fast activity have been observed in patients during HALCION therapy and are of no known significance.

DRUG ABUSE AND DEPENDENCE: *Controlled Substance:* HALCION Tablets are a Controlled Substance in Schedule IV. *Abuse and Dependence:* Withdrawal symptoms have occurred following abrupt discontinuance of benzodiazepines. Patients with a history of seizures are at particular risk. Addiction-prone patients should be closely monitored. Repeat prescriptions should be limited to those under medical supervision.

OVERDOSAGE: Because of the potency of triazolam, overdosage may occur at 2 mg, four times the maximum recommended therapeutic dose (0.5 mg). Manifestations of overdosage include somnolence, confusion, impaired coordination, slurred speech, and ultimately, coma. Respiration, pulse, and blood pressure should be monitored and supported by general measure when necessary. Immediate gastric lavage should be performed. Multiple agents may have been ingested.

Store at controlled room temperature 15°-30°C (59°-86°F).

Caution: Federal law prohibits dispensing without prescription.

B-3-S

continued from page 635

(prolactin-inhibiting factor) over the pituitary, the mechanism by which psychological disturbances may cause or be related to galactorrhea in the absence of hyperprolactinemia is unknown. Kleinberg et al¹ suggested that in primary idiopathic galactorrhea, the breast had adapted itself to secrete milk in the presence of normal prolactin levels. Perhaps it is possible that another nonprolactin mechanism that is stimulated by psychological factors is involved in the secretion of milk.

Further studies are needed to elucidate the role of psychological aspects in the etiology of many endocrinological disturbances.

References

- Kleinberg DL, Noel GL, Frantz AG: Galactorrhea: A study of 235 cases including 48 with pituitary tumors. *N Engl J Med* 1977; 296: 589-600
- Nyrjesy I: Galactorrhea without amenorrhea. *Obstet Gynecol* 1968; 32:52-57
- Friedman S, Goldfien A: Breast secretions in normal women. *Am J Obstet Gynecol* 1969; 104:846-849
- Tyson JE, Andreassen B, Smith J, et al: Neuroendocrine dysfunction with psychogenic implication in post-pill galactorrhea-amenorrhea. *Obstet Gynecol* 1975; 46:1-6
- Overall JE, Gomez-Mont F: The MMPI-168 for psychiatric screening. *J Educ Psychol Meas* 1974; 34:315-319
- Overall JE, Higgins W, De Schweinitz A: Comparison of differential diagnostic discrimination for abbreviated and standard MMPI. *J Clin Psychol* 1976; 32:237-245
- Dahistrom WG, Welsh GS, Dahistrom LE: *An MMPI Handbook*. Minneapolis, University of Minnesota Press, 1973
- Zacur HA, Chapanis NP, Lake CR, et al: Galactorrhea-amenorrhea: Psychological interaction with neuroendocrine function. *Am J Obstet Gynecol* 1976; 125:859-862
- Nicolls CS, Talwalker PK, Meites J: Initiation of lactation in rats by non-specific stress. *Am J Physiol* 1960; 198:1103-1109
- Naguib YA, Darwish NA, Shaarawy M, et al: Endocrinologic and psychologic aspects of galactorrhea associated with normal menstrual cycles. *Int J Gynecol Obstet* 1981; 19:285-290